Rosuvastatin in elderly patients

Area of Science:

• Cardiology
• Pharmacology

Background:

• Elderly individuals face a higher risk of cardiovascular disease due to atherosclerotic lesion accumulation.
• HMG-CoA reductase inhibitor (statin) therapy is generally effective and well-tolerated in older patients.

Purpose of the Study:

• To evaluate the advantages of rosuvastatin in treating elderly patients with cardiovascular risk factors.
• To highlight rosuvastatin's potential benefits concerning efficacy, drug interactions, and management of comorbidities in the elderly population.

Main Methods:

• This is a review of existing literature and clinical data on rosuvastatin use in the elderly.
• Analysis focused on efficacy at low doses, drug-drug interactions, and impact on common comorbidities.

Main Results:

• Rosuvastatin demonstrates high efficacy at low starting doses, facilitating achievement of low-density lipoprotein-cholesterol goals.
• It exhibits a favorable safety profile with limited interactions with cytochrome P450 3A4 metabolized drugs.
• The drug has shown efficacy in elderly patients with renal impairment and diabetes mellitus.

Conclusions:

• Rosuvastatin presents several advantages for elderly patients, including potent lipid-lowering effects, a favorable interaction profile, and efficacy in managing common comorbidities.
• Further cardiovascular endpoint data are needed to fully establish its long-term benefits in this population.